Loading organizations...
§ Private Profile · Manhattan, NY, USA
Medical technology developing mesh-free solutions for Pelvic Organ Prolapse (POP) affecting women's pelvic floor. For medical professionals.
FemSelect has raised $12.0M across 2 funding rounds.
Key people at FemSelect.
FemSelect has raised $12.0M in total across 2 funding rounds.
Based in Modi'in, Israel, FemSelect is a medical technology company that develops minimally invasive, mesh-free surgical solutions for women suffering from pelvic organ prolapse. The company's flagship product, EnPlace, is an FDA-cleared and CE-marked system that allows healthcare providers to suture pelvic floor ligaments during a same-day outpatient procedure. To date, the proprietary medical device has been utilized by specialized urogynecologists and medical institutions to treat over 3,000 patients globally. FemSelect has raised a total of $9.58 million in venture funding, which includes a $9 million Series B round led by institutional investors TriVentures and New Age Ventures. The organization is currently managed by Chief Executive Officer Sasha Schrode and President Debbie Garner to drive commercial growth. The enterprise was founded in 2012 by Medical Director Professor Menahem Neuman and Vice President of Research and Development Boaz Harari.
FemSelect has raised $12.0M across 2 funding rounds. Most recently, it raised $9.0M Series B in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 20, 2022 | $9M Series B | NEW AGE Ventures, Triventures | Keiretsu Capital, Keiretsu Forum MID Atlantic, Meda Angels, MID Atlantic BIO Angels, RAD BioMed, Robin Hood Ventures, Transpacific Venture Partners | Announced |
| Mar 13, 2018 | $3M Series A | Bernie Rudnick | — | Announced |
Key people at FemSelect.
FemSelect has raised $12.0M in total across 2 funding rounds.
FemSelect's investors include New Age Ventures, Triventures, Keiretsu Capital, Keiretsu Forum Mid-Atlantic, MEDA Angels, Mid Atlantic Bio Angels, RAD BioMed, Robin Hood Ventures, Transpacific Venture Partners, Bernie Rudnick.
FemSelect is a women-led medical technology company specializing in innovative solutions for pelvic organ prolapse (POP), a condition affecting one in four adult women. Its flagship product, the EnPlace® system, is a minimally invasive, mesh-free, and dissection-free technology designed to treat POP with fewer complications, reduced pain, minimal scarring, and quicker recovery compared to traditional surgical methods. FemSelect serves women suffering from pelvic floor disorders, offering them safer and more accessible treatment options that preserve uterine conservation and improve quality of life. The company is expanding globally and has recently broadened its portfolio to include treatments for urinary incontinence through a partnership with Elidah, reflecting strong growth momentum fueled by successful funding rounds and strategic partnerships[1][2][3].
Founded originally in Israel, FemSelect emerged from the need to address the significant unmet medical needs in women’s pelvic health with less invasive and more patient-friendly technologies. The company was co-led by Renee Selman (Executive Chairwoman) and later appointed Sasha Schrode as CEO, who brought extensive healthcare innovation and commercial expertise from her previous leadership at Serpex Medical. The idea for EnPlace grew from clinical experience and the desire to offer a safer alternative to mesh-based surgeries, which have been associated with complications. Early traction included FDA clearance, CE marking, and strategic partnerships such as the sales agreement with LiNA Medical USA to accelerate U.S. market penetration. The company’s relocation of its headquarters to the U.S. aligns with its largest market focus and growth ambitions[2][4][5].
FemSelect rides the growing trend of personalized, minimally invasive medical technologies that prioritize patient safety and quality of life, especially in women’s health—a historically underserved area. The timing is critical as awareness of pelvic organ prolapse and urinary incontinence rises, alongside increasing demand for alternatives to traditional mesh surgeries. Market forces such as regulatory scrutiny on mesh products and a global push for women-centric healthcare innovations favor FemSelect’s approach. By expanding its product portfolio and geographic footprint, FemSelect influences the broader ecosystem by setting new standards for pelvic health treatment and empowering healthcare providers with advanced, patient-friendly tools[1][3][5].
FemSelect is poised for significant growth as it leverages recent funding, leadership enhancements, and strategic U.S. market positioning. Future trends shaping its journey include increasing awareness of pelvic health issues, technological advances in minimally invasive procedures, and expanding digital health integration for patient monitoring and education. The company’s influence is likely to evolve from a niche innovator to a global leader in women’s pelvic health solutions, potentially expanding into adjacent markets and continuing to build a comprehensive platform of women’s health technologies. FemSelect’s mission to redefine care for millions of underserved women worldwide remains central as it scales its impact[2][3][5].
